Avalo Therapeutics (NASDAQ:AVTX) Raised to Strong-Buy at Wolfe Research

Avalo Therapeutics (NASDAQ:AVTX) was upgraded by investment analysts at Wolfe Research to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

AVTX has been the subject of a number of other research reports. Guggenheim assumed coverage on Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 target price for the company. Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. BTIG Research reaffirmed a “buy” rating and set a $40.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday, March 24th. Mizuho raised Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, HC Wainwright raised their price objective on Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Avalo Therapeutics presently has an average rating of “Buy” and an average price target of $44.83.

Avalo Therapeutics Stock Down 1.4%

AVTX opened at $14.21 on Wednesday. The stock has a market cap of $323.85 million, a PE ratio of -2.48 and a beta of 0.93. The business has a 50 day moving average of $15.52 and a 200-day moving average of $16.07. Avalo Therapeutics has a 52 week low of $3.39 and a 52 week high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter, compared to analysts’ expectations of ($0.21) million. Equities analysts anticipate that Avalo Therapeutics will post -19.07 EPS for the current year.

Insider Buying and Selling

In related news, insider Mittie Doyle sold 25,492 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the transaction, the insider owned 3,622 shares of the company’s stock, valued at $58,495.30. This trade represents a 87.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Christopher Ryan Sullivan sold 7,980 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $17.15, for a total value of $136,857.00. Following the transaction, the chief financial officer directly owned 17,338 shares of the company’s stock, valued at approximately $297,346.70. This trade represents a 31.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 46,100 shares of company stock valued at $764,724. 3.03% of the stock is owned by corporate insiders.

Institutional Trading of Avalo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of AVTX. BIT Capital GmbH bought a new stake in shares of Avalo Therapeutics in the 3rd quarter worth $25,000. PFS Partners LLC increased its holdings in shares of Avalo Therapeutics by 100.0% in the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after purchasing an additional 1,000 shares in the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Avalo Therapeutics in the 2nd quarter worth $56,000. Dimensional Fund Advisors LP bought a new stake in shares of Avalo Therapeutics in the 3rd quarter worth $143,000. Finally, Jump Financial LLC bought a new stake in shares of Avalo Therapeutics in the 4th quarter worth $238,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.